Clinical Trials
10 trialsNCT04623541 2026-06-02
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT05734495 2026-05-28
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04662255 2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04666038 2026-04-24
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT07162181 2026-04-17
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Eli Lilly and Company
Phase 2 Active not recruiting
NCT06522386 2026-04-16
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05677919 2026-02-12
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 2 Active not recruiting
NCT04965493 2026-01-29
BRUIN CLL-322
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05023980 2026-01-22
BRUIN CLL-313
Eli Lilly and Company
Phase 3 Active not recruiting